Home > Boards > US Listed > Medical - Equipment > Cytosorbents Corporation (CTSO)

Dr. Harbord says the patient’s clinical improvement

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
biotech48 Member Profile
 
Followed By 2
Posts 581
Boards Moderated 0
Alias Born 03/22/12
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 1/24/2022 4:31:32 PM
New Publication Reports Significant Reductions in Perioperative Bleeding Complications Following Acute Aortic Dissection Surgery using CytoSorbents' Antithrombotic Drug Removal Technology PR Newswire (US) - 1/24/2022 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/20/2022 4:32:05 PM
Leerink Partners Thinks Cytosorbents’ Stock is Going to Recover TipRanks - 1/20/2022 3:46:07 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/18/2022 4:32:30 PM
CytoSorbents jumps 1.86% on prelim FY21 and Q4 revenue above the consensus Seeking Alpha - 1/18/2022 7:35:44 AM
CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2021 Revenue PR Newswire (US) - 1/18/2022 7:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/7/2022 5:11:35 PM
Dawson James Remains a Buy on Cytosorbents (CTSO) TipRanks - 1/5/2022 4:10:04 AM
Dawson James Sticks to Their Buy Rating for Cytosorbents (CTSO) TipRanks - 1/5/2022 4:08:54 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/30/2021 5:29:04 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 12/30/2021 5:27:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/21/2021 9:01:13 AM
CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular PR Newswire (US) - 12/21/2021 7:05:00 AM
CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO) PR Newswire (US) - 12/20/2021 7:10:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 12/13/2021 5:01:41 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/13/2021 9:06:01 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/26/2021 6:11:44 PM
CytoSorbents to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and Jefferies London Healthcare Conference PR Newswire (US) - 11/15/2021 4:30:00 PM
Cytosorbents EPS misses by $0.03, beats on revenue Seeking Alpha - 11/4/2021 4:29:11 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/4/2021 4:15:41 PM
CytoSorbents Reports Full Third Quarter 2021 Financial and Operational Results PR Newswire (US) - 11/4/2021 4:15:00 PM
Cytosorbents Q3 2021 Earnings Preview Seeking Alpha - 11/3/2021 5:35:41 PM
CytoSorbents Comments on REMOVE Study Presentation PR Newswire (US) - 10/20/2021 7:05:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/15/2021 6:26:17 AM
biotech48   Monday, 04/30/18 12:13:42 AM
Re: jlo46383 post# 11469
Post # of 27014 
Dr. Harbord says the patient’s clinical improvement
was immediate and significant, with hemodynamic stabilization during the
first treatment, followed by enhanced liver function and mental status.
“We were able to demonstrate marked improvement in the patient’s
clinical illness by removing the cytokines, which were responsible for
his hypotension and shock,” Dr. Harbord says. “The dose of pressors,
the day-to-day bloodwork—all of it improved, and we saw a 56 percent
reduction in cytokines over the course of therapy.”
Dr. Harbord says that CytoSorb is nonspecific, removing many elevated
cytokines (both pro- and anti-inflammatory), but he adds that the risks
are not significant and that the risk of not intervening may be greater.
Given the results achieved in this investigational use, he says, cytokine
hemadsorption has potential as a treatment for HLH, a disease with a
mortality rate in excess of 50 percent.
“I think we demonstrated real proof-of-concept benefit for patients
through investigational use,” Dr. Harbord says. “I would not hesitate to
use it again, and I would hope it gives other nephrologists the confidence
to adopt it based on our experience at Mount Sinai.”

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences